Combining targeted, focused ultrasound and immunotherapy drugs could work as a new treatment for pancreatic cancers, a new study has shown.

Scientists have revealed how cancer can resist PARP inhibitors, a precision medicine used to treat thousands of patients worldwide.

The first cancer patients are to receive doses of an innovative new drug that targets a master regulatory pathway in cells, as part of a new clinical trial.